NEW DELHI: With an purpose to launch vaccine for Influenza H1N1 A Virus (swine flu) in India, Cadila Pharmaceutical will search the government's nod in two days for initiating medical trials on this regard.
Cadila Pharmaceutical Ltd (CPL) had set up a three way partnership 'CPL Biologicals Pvt Ltd' with the US-based vaccine maker Novavax for manufacturing and creating a bunch of vaccines, including for swine flu, in India.
"The joint venture is going to file the application with the Drug Controller General of India (DCGI) in the next two days for phase-I clinical trials for swine flu vaccine," CPL Chairman and Managing Director I A Modi mentioned.
Modi expressed self assurance that Cadila would be the first Indian pharma company to launch the swine flu vaccine in India by December.
"If we get the permission of DCGI soon, then with the advanced technology available from our partner, (we) would be able to launch it in India by December this year," Modi mentioned.
With its current facility, Cipla can produce up to a million doses of the vaccine monthly, which will also be scaled up to two million doses, Modi mentioned.
"Novavax has already received permission for clinical trials from the US Federal Drug Administration and if we get it soon, we can simultaneously start the trials," he added.
The govt has already indicated that swine flu similar packages it will transparent on a fast track basis and the company is hopeful of having immediate popularity of it, Modi added.
He mentioned to protect from swine flu pandemic, two dosages of the vaccine are required over two weeks.
The JV has already started building a facility with an estimated investment of Rs 100 crore. In the three way partnership Cadila has 80 in keeping with cent stake and the rest 20 in keeping with cent is held by Novavax.
Besides this, Cadila Pharma also holds five.75 in keeping with cent stake in Novavax Inc US and has a place on the board of directors of the US-based company.
Cadila Pharmaceutical Ltd (CPL) had set up a three way partnership 'CPL Biologicals Pvt Ltd' with the US-based vaccine maker Novavax for manufacturing and creating a bunch of vaccines, including for swine flu, in India.
"The joint venture is going to file the application with the Drug Controller General of India (DCGI) in the next two days for phase-I clinical trials for swine flu vaccine," CPL Chairman and Managing Director I A Modi mentioned.
Modi expressed self assurance that Cadila would be the first Indian pharma company to launch the swine flu vaccine in India by December.
"If we get the permission of DCGI soon, then with the advanced technology available from our partner, (we) would be able to launch it in India by December this year," Modi mentioned.
With its current facility, Cipla can produce up to a million doses of the vaccine monthly, which will also be scaled up to two million doses, Modi mentioned.
"Novavax has already received permission for clinical trials from the US Federal Drug Administration and if we get it soon, we can simultaneously start the trials," he added.
The govt has already indicated that swine flu similar packages it will transparent on a fast track basis and the company is hopeful of having immediate popularity of it, Modi added.
He mentioned to protect from swine flu pandemic, two dosages of the vaccine are required over two weeks.
The JV has already started building a facility with an estimated investment of Rs 100 crore. In the three way partnership Cadila has 80 in keeping with cent stake and the rest 20 in keeping with cent is held by Novavax.
Besides this, Cadila Pharma also holds five.75 in keeping with cent stake in Novavax Inc US and has a place on the board of directors of the US-based company.
Cadila to apply for clinical trials for swine flu vaccine
![Cadila to apply for clinical trials for swine flu vaccine]()
Reviewed by Kailash
on
March 05, 2018
Rating:
